2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
2 t sittenUPDATED: Sept. 19, 2026 As expected, the past U.S. Labor Day holiday took a toll on obesity drugs' prescription numbers. According to IQVIA data cited by Citi, weekly scripts for Novo's Wegovy pill dropped roughly 12% sequentially to about 161K for the last week. The decline for Foundayo was modest, at just 1%, as the Lilly drug still managed to rake in more than 47K scripts. Lilly this week said Foundayo captured more than 30% of new patients in the U.S. market for oral obesity treatments, Reuters reported. Citing Bloomberg Symphony data, Jefferies analysts suggested in a Friday note that Foundayo's recent acceleration "has been driven primarily by retail/commercial channels." Elsewhere, Lilly's total Zepbound scripts were down 8.5% week over week, but the GIP/GLP-1 drug expanded its market share by 0.4% versus Novo's Wegovy franchise, whose scripts decreased 10% during the period.
·3 t sitten · MuokattuEli can sell EVERYTHING! Eli captures 22.6% new customers! (see picture) Eli ads: At the same price as the Wegovy pill, our Foundayo offers a 12.4% weight loss, though there is no cardiovascular evidence yet. Come by and get some donuts! Love you baby♥️ Novo ads: 16.6% weight loss, stronger demonstrated cardiovascular evidence since 2017 with Ozempic. Hygge 😴 Americans can just ask their health minister, Robert Kennedy Jr. He knows (that WP is #1) better. :) Just kidding. Americans, here you go, just copy/paste this to any of your AI buddy: DO YOU AGREE THAT, IF CARDIOVASCULAR PROTECTION IS A KEY FACTOR, SEMAGLUTIDE HAS YEARS OF EVIDENCE SINCE 2017 TO PROVE ITS CARDIOVASCULAR PROTECTION OVER FOUNDAYO? 2 extra free beers every day, and yet they choose Eli-Fo ??? Houston, Houston, We have a problem.... Have a good weekend and a good meeting on Monday. Ps: Imagine if Novo got Zepbound and Eli got Wegovy, I am absolutely certain that Eli is still ahead!
LLY then went down a total of 8 % on their prescriptions for obesity products, so even though they capture 22.6 % new customers on pill sales, they apparently lose on their other pipeline of obesity-related products. That's how you distort the market into believing things are going super well; in the EU, it would be false marketing.
·4 t sitten · MuokattuAgreement on Greenland - I wonder if that doesn't move Denmark several places down the list of friendly democracies that Trump wants to punish. I have always had in the back of my mind that he would look for a method to soften Denmark by finding ways to harm us economically. Those who bring the most money to the country would, of course, constitute the most obvious targets.. So it feels like a relief after all that he has gotten an agreement he can paint as something huge, because that probably lifts some of the risk out of the medicine, wind, and energy stocks. Not least Novo.
An agreement with Trump is not worth the paper it's written on - I think there are enough examples of that within the last 18 months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
- 2 t sittenUPDATED: Sept. 19, 2026 As expected, the past U.S. Labor Day holiday took a toll on obesity drugs' prescription numbers. According to IQVIA data cited by Citi, weekly scripts for Novo's Wegovy pill dropped roughly 12% sequentially to about 161K for the last week. The decline for Foundayo was modest, at just 1%, as the Lilly drug still managed to rake in more than 47K scripts. Lilly this week said Foundayo captured more than 30% of new patients in the U.S. market for oral obesity treatments, Reuters reported. Citing Bloomberg Symphony data, Jefferies analysts suggested in a Friday note that Foundayo's recent acceleration "has been driven primarily by retail/commercial channels." Elsewhere, Lilly's total Zepbound scripts were down 8.5% week over week, but the GIP/GLP-1 drug expanded its market share by 0.4% versus Novo's Wegovy franchise, whose scripts decreased 10% during the period.
- ·3 t sitten · MuokattuEli can sell EVERYTHING! Eli captures 22.6% new customers! (see picture) Eli ads: At the same price as the Wegovy pill, our Foundayo offers a 12.4% weight loss, though there is no cardiovascular evidence yet. Come by and get some donuts! Love you baby♥️ Novo ads: 16.6% weight loss, stronger demonstrated cardiovascular evidence since 2017 with Ozempic. Hygge 😴 Americans can just ask their health minister, Robert Kennedy Jr. He knows (that WP is #1) better. :) Just kidding. Americans, here you go, just copy/paste this to any of your AI buddy: DO YOU AGREE THAT, IF CARDIOVASCULAR PROTECTION IS A KEY FACTOR, SEMAGLUTIDE HAS YEARS OF EVIDENCE SINCE 2017 TO PROVE ITS CARDIOVASCULAR PROTECTION OVER FOUNDAYO? 2 extra free beers every day, and yet they choose Eli-Fo ??? Houston, Houston, We have a problem.... Have a good weekend and a good meeting on Monday. Ps: Imagine if Novo got Zepbound and Eli got Wegovy, I am absolutely certain that Eli is still ahead!LLY then went down a total of 8 % on their prescriptions for obesity products, so even though they capture 22.6 % new customers on pill sales, they apparently lose on their other pipeline of obesity-related products. That's how you distort the market into believing things are going super well; in the EU, it would be false marketing.
- ·4 t sitten · MuokattuAgreement on Greenland - I wonder if that doesn't move Denmark several places down the list of friendly democracies that Trump wants to punish. I have always had in the back of my mind that he would look for a method to soften Denmark by finding ways to harm us economically. Those who bring the most money to the country would, of course, constitute the most obvious targets.. So it feels like a relief after all that he has gotten an agreement he can paint as something huge, because that probably lifts some of the risk out of the medicine, wind, and energy stocks. Not least Novo.An agreement with Trump is not worth the paper it's written on - I think there are enough examples of that within the last 18 months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
45 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNovo Nordisk has entered into an agreement to acquire three obesity programs from the American biotech company Kallyope, all based on non-incretin-based mechanisms. * The most advanced program is K-554, which is described as IND-ready – i.e., ready to proceed towards clinical trials. * The two other programs include: * a potential first-in-class peptide * a small-molecule program targeting the same new target * as well as a separate small-molecule receptor agonist program, which is still in lead optimization. * The specific targets and the financial value of the agreement have not been disclosed. * The agreement was not announced via a traditional press release but was mentioned by Jacob Petersen, Novo Nordisk's Head of Global Research, and Tamara Darsow, Head of Global Business Development, on LinkedIn. Novo has subsequently confirmed to Fierce Biotech that the agreement is new. * K-554 is not a new program in itself – Kallyope has previously mentioned the candidate. What is new is that Novo is now taking over K-554 along with two additional obesity programs. Background: Kallyope is a New York-based biotech company that develops drugs based on neural signaling mechanisms, including in metabolism and migraine. The company investigates, among other things, how signals between the gut, the vagus nerve, and the brain affect appetite and food intake. In short: Novo is thus expanding its obesity pipeline with three non-incretin-based programs, with K-554 being the most advanced. This is interesting because it indicates that Novo continues to seek new mechanisms beyond GLP-1/GIP, rather than exclusively developing the next generation of incretin drugs.What can it be used for? K-554 is developed to affect the brain's/neural circuits that regulate appetite and satiety, via a mechanism not based on GLP-1 or other incretins. Kallyope describes it as a weekly injection that activates a non-incretin peptide receptor. The goal is to create satiety without necessarily eliciting the same unpleasant signals that can accompany some existing obesity treatments.
- 2 t sittenUPDATED: Sept. 19, 2026 As expected, the past U.S. Labor Day holiday took a toll on obesity drugs' prescription numbers. According to IQVIA data cited by Citi, weekly scripts for Novo's Wegovy pill dropped roughly 12% sequentially to about 161K for the last week. The decline for Foundayo was modest, at just 1%, as the Lilly drug still managed to rake in more than 47K scripts. Lilly this week said Foundayo captured more than 30% of new patients in the U.S. market for oral obesity treatments, Reuters reported. Citing Bloomberg Symphony data, Jefferies analysts suggested in a Friday note that Foundayo's recent acceleration "has been driven primarily by retail/commercial channels." Elsewhere, Lilly's total Zepbound scripts were down 8.5% week over week, but the GIP/GLP-1 drug expanded its market share by 0.4% versus Novo's Wegovy franchise, whose scripts decreased 10% during the period.
- ·3 t sitten · MuokattuEli can sell EVERYTHING! Eli captures 22.6% new customers! (see picture) Eli ads: At the same price as the Wegovy pill, our Foundayo offers a 12.4% weight loss, though there is no cardiovascular evidence yet. Come by and get some donuts! Love you baby♥️ Novo ads: 16.6% weight loss, stronger demonstrated cardiovascular evidence since 2017 with Ozempic. Hygge 😴 Americans can just ask their health minister, Robert Kennedy Jr. He knows (that WP is #1) better. :) Just kidding. Americans, here you go, just copy/paste this to any of your AI buddy: DO YOU AGREE THAT, IF CARDIOVASCULAR PROTECTION IS A KEY FACTOR, SEMAGLUTIDE HAS YEARS OF EVIDENCE SINCE 2017 TO PROVE ITS CARDIOVASCULAR PROTECTION OVER FOUNDAYO? 2 extra free beers every day, and yet they choose Eli-Fo ??? Houston, Houston, We have a problem.... Have a good weekend and a good meeting on Monday. Ps: Imagine if Novo got Zepbound and Eli got Wegovy, I am absolutely certain that Eli is still ahead!LLY then went down a total of 8 % on their prescriptions for obesity products, so even though they capture 22.6 % new customers on pill sales, they apparently lose on their other pipeline of obesity-related products. That's how you distort the market into believing things are going super well; in the EU, it would be false marketing.
- ·4 t sitten · MuokattuAgreement on Greenland - I wonder if that doesn't move Denmark several places down the list of friendly democracies that Trump wants to punish. I have always had in the back of my mind that he would look for a method to soften Denmark by finding ways to harm us economically. Those who bring the most money to the country would, of course, constitute the most obvious targets.. So it feels like a relief after all that he has gotten an agreement he can paint as something huge, because that probably lifts some of the risk out of the medicine, wind, and energy stocks. Not least Novo.An agreement with Trump is not worth the paper it's written on - I think there are enough examples of that within the last 18 months.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 298 | - | - | ||
| 32 | - | - | ||
| 600 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt